Liquidia (NASDAQ:LQDA) Releases Earnings Results, Misses Estimates By $0.02 EPS

Liquidia (NASDAQ:LQDA) released its quarterly earnings data on Wednesday. The company reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.02), FiscalAI reports. The firm had revenue of $171.68 million for the quarter, compared to analyst estimates of $168.48 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The company’s revenue was up 1842.1% compared to the same quarter last year. During the same period last year, the business earned ($0.49) EPS.

Here are the key takeaways from Liquidia’s conference call:

• YUTREPIA continued strong commercial growth, with approximately 5,900 unique prescriptions, more than 5,000 patients started, and over 1,100 prescribing physicians as of July 31. Q2 net product sales reached $170.4 million, up 31% sequentially, and YUTREPIA represented nearly 30% of the inhaled treprostinil market.
• Liquidia reported improving profitability and cash generation, including $74.7 million of net income, $96.3 million of adjusted EBITDA, and $284.2 million in cash and equivalents. Management reiterated confidence in exceeding $1 billion in net revenue in 2027 while continuing to fund pipeline investments.
• The company is expanding its commercial organization and believes substantial opportunity remains in community-based PAH and PH-ILD diagnosis and treatment, as well as switches from competing inhaled, oral, and parenteral prostacyclin therapies. Payer access was described as broadly available and generally at parity.
• Liquidia plans significant R&D expansion, with second-half 2026 R&D expense expected to be double the first half and additional increases anticipated in 2027. The company has 10 YUTREPIA and L606 studies underway or planned, including the Phase III RESPIRE trial for twice-daily L606 and future studies in Raynaud’s phenomenon and progressive pulmonary fibrosis.
• The company is still awaiting a decision in the ’327 litigation, with management saying a ruling could come at any time and acknowledging possible outcomes including royalties or injunctive relief if the decision goes against Liquidia.

Liquidia Price Performance

Shares of NASDAQ:LQDA opened at $78.79 on Thursday. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18. The firm has a market capitalization of $7.01 billion, a PE ratio of 562.83 and a beta of 0.58. Liquidia has a twelve month low of $21.15 and a twelve month high of $93.61. The company has a 50-day moving average price of $78.22 and a two-hundred day moving average price of $54.77.

Liquidia News Summary

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: YUTREPIA growth remained strong: Second-quarter net product sales reached approximately $170.4 million, up 31% sequentially. Liquidia reported about 5,900 unique prescriptions and more than 5,000 treated patients since the product’s June 2025 launch. Liquidia Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Profitability and cash improved: Liquidia posted $171.7 million in revenue, $74.7 million in net income and $96.3 million in adjusted EBITDA. Cash and equivalents increased to $284.2 million, supporting ongoing development programs. Liquidia Q2 Net Income Reaches $74.7 Million As YUTREPIA Sales Rise
• Positive Sentiment: Analysts raised targets: Needham increased its target to $110 and BTIG lifted its target to $111, both maintaining buy ratings. Bank of America raised its target to $92, although it retained a neutral rating. These revisions indicate continued confidence in YUTREPIA’s commercial ramp. Analyst Price Target Updates
• Neutral Sentiment: Management reaffirmed its goal of exceeding $1 billion in net revenue in 2027 and is advancing 10 clinical studies for YUTREPIA and L606, though higher second-half research and development spending could affect near-term margins.
• Negative Sentiment: Adjusted earnings missed the broader consensus: Diluted EPS was $0.74, below the $0.76 consensus cited by several reports, despite exceeding the $0.70 Zacks estimate. The miss likely amplified selling pressure because the stock already reflects substantial optimism. Liquidia Shares Fall After Second-Quarter Earnings Miss
• Negative Sentiment: Reported insider activity is heavily weighted toward selling, with 116 open-market sales versus one purchase during the past six months. That pattern may raise valuation and sentiment concerns for investors.

Analyst Upgrades and Downgrades

LQDA has been the topic of several research reports. HC Wainwright set a $36.00 price target on Liquidia in a report on Friday, July 24th. Bank of America lifted their target price on shares of Liquidia from $79.00 to $92.00 and gave the stock a “neutral” rating in a research report on Thursday. Needham & Company LLC upped their price target on shares of Liquidia from $70.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday. Stephens set a $130.00 price objective on shares of Liquidia in a research note on Friday, July 24th. Finally, Royal Bank Of Canada set a $130.00 price objective on Liquidia in a report on Friday, July 24th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $94.92.

Insider Activity at Liquidia

In related news, insider Sarah Krepp sold 7,864 shares of the company’s stock in a transaction that occurred on Monday, July 13th. The shares were sold at an average price of $71.51, for a total transaction of $562,354.64. Following the sale, the insider directly owned 117,178 shares in the company, valued at approximately $8,379,398.78. This represents a 6.29% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Jason Adair sold 688 shares of the firm’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $87.53, for a total transaction of $60,220.64. Following the completion of the transaction, the insider directly owned 216,438 shares of the company’s stock, valued at approximately $18,944,818.14. This trade represents a 0.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 1,781,861 shares of company stock worth $124,407,112 in the last ninety days. Insiders own 25.60% of the company’s stock.

Hedge Funds Weigh In On Liquidia

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. bought a new position in Liquidia during the 4th quarter worth approximately $25,000. Alliancebernstein L.P. boosted its stake in shares of Liquidia by 1.4% during the third quarter. Alliancebernstein L.P. now owns 67,050 shares of the company’s stock valued at $1,525,000 after purchasing an additional 900 shares during the period. AQR Capital Management LLC grew its holdings in shares of Liquidia by 9.3% in the fourth quarter. AQR Capital Management LLC now owns 13,966 shares of the company’s stock worth $482,000 after purchasing an additional 1,187 shares during the last quarter. Creative Planning increased its stake in shares of Liquidia by 5.4% in the third quarter. Creative Planning now owns 28,298 shares of the company’s stock worth $643,000 after buying an additional 1,458 shares during the period. Finally, Raymond James Financial Inc. raised its holdings in Liquidia by 4.1% during the 3rd quarter. Raymond James Financial Inc. now owns 39,064 shares of the company’s stock valued at $888,000 after buying an additional 1,549 shares during the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).